Impaired incretin secretion and pancreatic dysfunction with older age and diabetes

Metabolism. 2014 Jul;63(7):922-9. doi: 10.1016/j.metabol.2014.04.004. Epub 2014 Apr 12.

Abstract

Objective: To estimate the impact of aging and diabetes on insulin sensitivity, beta-cell function, adipocytokines, and incretin production.

Methods: Hyperglycemic clamps, arginine tests and meal tolerance tests were performed in 50 non-obese subjects to measure insulin sensitivity (IS) and insulin secretion as well as plasma levels of glucagon, GLP-1 and GIP. Patients with diabetes and healthy control subjects were divided into the following groups: middle-aged type 2 diabetes (MA-DM), aged Type 2 diabetes (A-DM) and middle-aged or aged subjects with normal glucose tolerance (MA-NGT or A-NGT).

Results: IS, as determined by the homeostasis model assessment, glucose infusion rate, and oral glucose insulin sensitivity, was reduced in the aged and DM groups compared with MA-NGT, but it was similar in the MA-DM and A-DM groups. Insulinogenic index, first and second phase insulin secretion and the disposition indices, but not insulin response to arginine, were reduced in the aged and DM groups. Postprandial glucagon production was higher in MA-DM compared to MA-NGT. Whereas the GLP-1 production was reduced in A-DM, no differences between groups were observed in GIP production.

Conclusions: In non-obese subjects, diabetes and aging impair insulin sensitivity. Insulin production is reduced by aging, and diabetes exacerbates this condition. Aging associated defects superimposed diabetic physiopathology, particularly regarding GLP-1 production. On the other hand, the glucose-independent secretion of insulin was preserved. Knowledge of the complex relationship between aging and diabetes could support the development of physiopathological and pharmacological based therapies.

Trial registration: ClinicalTrials.gov NCT00843232 NCT00843479.

Keywords: Beta-cell function; GLP-1; Glucagon; Incretin; Insulin sensitivity.

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiponectin / blood
  • Adiponectin / metabolism*
  • Adipose Tissue / metabolism
  • Adult
  • Aged
  • Aging*
  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / physiopathology*
  • Down-Regulation*
  • Gastric Inhibitory Polypeptide / blood
  • Gastric Inhibitory Polypeptide / metabolism
  • Glucagon / blood
  • Glucagon / metabolism
  • Glucagon-Like Peptide 1 / blood
  • Glucagon-Like Peptide 1 / metabolism*
  • Humans
  • Incretins / blood
  • Incretins / metabolism
  • Insulin / blood
  • Insulin / metabolism*
  • Insulin Resistance
  • Insulin Secretion
  • Male
  • Middle Aged
  • Pancreas / metabolism
  • Pancreas / physiopathology*
  • Postprandial Period
  • Up-Regulation

Substances

  • ADIPOQ protein, human
  • Adiponectin
  • Incretins
  • Insulin
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptide 1
  • Glucagon

Associated data

  • ClinicalTrials.gov/NCT00843232
  • ClinicalTrials.gov/NCT00843479